Pyoderma gangrenosum was first described as an extraintestinal manifestation of inflammatory bowel disease (IBD) by Brunsting and colleagues in 1930. 1 They described painful enlarging necrotic ulcers ...
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab ...
Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S. PG is a rare and debilitating autoimmune skin ...
Pyoderma gangrenosum is a diagnosis of exclusion, and the misdiagnosis of pyoderma gangrenosum can result in substantial complications in patients who have other causes of severe cutaneous ulceration.
People who have an inflammatory bowel disease like ulcerative colitis often have problems caused by inflammation in other parts of their bodies. One of these is a skin condition called pyoderma ...
Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S.PG is a rare and debilitating autoimmune skin ...
Pyoderma gangrenosum is a diagnosis of exclusion, and the misdiagnosis of pyoderma gangrenosum can result in substantial complications in patients who have other causes of severe cutaneous ulceration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results